Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-06: Form 8-K; Period of report 2014-11-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-09-09: Form 8-K; Period of report 2014-09-09; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2014-09-04: Form 8-K; Period of report 2014-09-03; Description 8.01 Other Events; Details 8.01.
- 2014-09-02: Form 8-K; Period of report 2014-09-02; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-06 | 8-K | 2014-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2014, Clovis Oncology, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2014. | a50978895.htm |
| 2014-09-09 | 8-K | 2014-09-09 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On September 9, 2014, Clovis Oncology, Inc. (the “Company”) consummated its previously announced offering of $287.5 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2021 (the “Notes”). 2.03 The information with respect to the Notes and the Indenture and set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information with respect to the Notes and the Indenture and set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d786138d8k.htm |
| 2014-09-04 | 8-K | 2014-09-03 | 8.01 Other Events | 8.01 On September 3, 2014, Clovis Oncology, Inc. (the “Company”) issued a press release announcing the pricing of $250 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. | d782690d8k.htm |
| 2014-09-02 | 8-K | 2014-09-02 | 8.01 Other Events | 8.01 On September 2, 2014, the Clovis Oncology, Inc. (the “Company”) issued a press release announcing its intention to offer $200 million aggregate principal amount of convertible senior notes due 2021, subject to market conditions and other factors, in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. | d783642d8k.htm |
| 2014-08-07 | 8-K | 2014-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2014, Clovis Oncology, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2014. | a50921229.htm |
| 2014-06-16 | 8-K | 2014-06-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Shareholders (the “Annual Meeting”) of Clovis Oncology, Inc. (the “Company”) was held on June 12, 2014. | d741921d8k.htm |
| 2014-06-02 | 8-K | 2014-05-31 | 8.01 Other Events | 8.01 On May 31, 2014, Clovis Oncology, Inc. (the “Company”) issued the first of three press releases announcing data being presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. | a50877271.htm |
| 2014-05-08 | 8-K | 2014-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2014, Clovis Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2014. | a50861728.htm |
| 2014-03-27 | 8-K | 2014-03-27 | 8.01 Other Events | 8.01 On March 27, 2014, Clovis Oncology, Inc. (the “Company”) issued a press release announcing that the Company reported at the 4th European Lung Cancer Conference in Geneva updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686 for the treatment of non-small cell lung cancer. | a50832677.htm |
| 2014-02-27 | 8-K | 2014-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2014, Clovis Oncology, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2013. | a50814003.htm |
| 2014-01-13 | 8-K | 2014-01-13 | 2.02 Results of Operations and Financial Condition | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2013, on January 13, 2014, Clovis Oncology, Inc. (the “Company”) issued a press release announcing that the Company had $323 million in cash as of December 31, 2013 and expects a cash burn of approximately $120 million for the year ending December 31, 2014. | a50781532.htm |